Lactoperoxidase 50unit medicated chewing gum sugar free
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 16 · Randomised trials: 2 · 1975–2026
Showing the 50 most relevant studies, sorted by most relevant.
K. D. Kussendrager, A. V. van Hooijdonk
British Journal of Nutrition, 2000
E. Seifu, E. Buys, E. Donkin
Trends in Food Science and Technology, 2005
Cappadona C, Rimoldi V, Tettamanzi F, et al.
2026
- Lactoperoxidase
- Oxidative Stress
- COVID-19
I. Gülçin, A. Scozzafava, C. Supuran, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry, 2016
L. Wolfson, S. Sumner
Journal of food protection, 1993
Reza N, Qader OAJA, Al-Rawas M, et al.
2026
AbstractSaliva plays an essential role in maintaining oral health by providing antimicrobial protection, regulating inflammation, and supporting tissue repair. Salivary enzymes such as lactoperoxidase, lysozyme, and lactoferrin are central to these protective functions. Conditions associated with reduced salivary flow, including xerostomia and postoperative states, impair these mechanisms and may result in delayed wound healing, microbial imbalance, discomfort, and increased susceptibility to infection. Conventional antiseptic mouthwashes, particularly chlorhexidine, are effective in controlling oral microorganisms but are frequently associated with adverse effects, including mucosal irritation, taste alteration, tooth discoloration, and concerns about long-term use. This structured review summarizes current evidence on natural enzyme-based mouthwashes, focusing on their mechanisms of action, potential benefits for oral wound healing and xerostomia management, and antimicrobial effects, and compares their efficacy and safety with conventional antiseptic agents.AbstractA focused literature search was conducted using PubMed, Scopus, and Web of Science from database inception to December 2025, supplemented by manual screening of reference lists. Peer-reviewed English-language studies, including clinical, experimental, observational, and in vitro research addressing enzyme-based mouthwashes, were considered.AbstractThe available literature suggests that enzyme-based mouthwashes exert selective antimicrobial effects by reducing pathogenic microorganisms and biofilm formation while largely preserving the commensal oral microbiota. Lactoperoxidase contributes to antimicrobial activity through hypothiocyanite generation, lysozyme disrupts bacterial cell walls, lactoferrin limits microbial growth through iron sequestration and immunomodulatory effects, and glucose oxidase supports sustained enzymatic activity. Clinical studies report improvements in oral wound healing, relief of xerostomia-related symptoms, enhanced oral comfort, and good tolerability when compared with conventional antiseptic mouthwashes. However, limitations include variability in enzyme stability, a narrower antimicrobial spectrum, and a limited number of long-term clinical trials.AbstractIn conclusion, enzyme-based mouthwashes appear to be safe and biocompatible adjuncts for supporting oral wound healing and managing xerostomia. By mimicking natural salivary defense mechanisms, they offer a microbiome-friendly, non-antibiotic alternative to conventional antiseptics in selected clinical situations. Further well-designed randomized clinical trials with standardized formulations and long-term follow-up are required to clarify their effectiveness and optimal clinical indications.
Abstract licence: CC BY
I. Gülçin, A. Scozzafava, C. Supuran, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry, 2016
F. Bafort, Olivier Parisi, J. Perraudin, et al.
Enzyme Research, 2014
G. Conner, M. Salathe, R. Forteza
American journal of respiratory and critical care medicine, 2002
Yu Morita, Kentaro Ishikawa, Manabu Nakano, et al.
Geriatrics & Gerontology International, 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.